azelaic bishydroxamic acid has been researched along with Duncan Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amlot, PL | 1 |
| Buck, M; Gabrielli, B; Krauer, KG; Parsons, PG; Sculley, TB | 1 |
2 other study(ies) available for azelaic bishydroxamic acid and Duncan Disease
| Article | Year |
|---|---|
Restoring cellular differentiatin in posttransplant lymphoproliferative disease.
Topics: B-Lymphocytes; Cell Differentiation; Cell Line; Cell Transformation, Viral; Enzyme Inhibitors; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoproliferative Disorders; Organ Transplantation | 2002 |
A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease.
Topics: B-Lymphocytes; Cell Death; Cell Line; Cell Transformation, Viral; Enzyme Inhibitors; G2 Phase; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphocyte Activation; Lymphoproliferative Disorders; Mitosis; Organ Transplantation; Virus Replication | 2002 |